Table 2.

Incidence rate^* of herpes zoster and herpes simplex associated with each biologic and tofacitinib

	Event	Person Years	Incidence Rate	Adjusted** Hazard Ratio (95% CI)
abatacept	450	8191.3	5.49 (5.01–6.03)	1.0 (referent)
adalimumab	295	5933.3	4.97 (4.44–5.57)	0.91 (0.78–1.06)
certolizumab	153	2748.9	5.57 (4.75–6.52)	1.01 (0.84–1.22)
etanercept	302	6087.5	4.96 (4.43–5.55)	0.89 (0.76–1.03)
golimumab	79	1452.9	5.44 (4.36–6.78)	1.02 (0.80–1.30)
infliximab	477	7760.5	6.15 (5.62–6.72)	1.10 (0.96–1.25)
rituximab	204	3739.6	5.46 (4.76–6.26)	0.97 (0.82–1.15)
tocilizumab	255	4068.2	6.27 (5.54–7.09)	1.16 (0.99–1.36)
tofacitinib	49	525.2	9.33 (7.05–12.3)	1.65 (1.21–2.23)

^*per 100 person years

^**adjusted for age, sex, baseline glucocorticoid use, methotrexate, number of biologics used, hospitalization, hospitalized infection, outpatient infection, and zoster vaccination